OQS
ITCI

Occudo Quantitative Strategies’s Intra-Cellular Therapies Inc. ITCI Stock Holding History

Occudo Quantitative Strategies’s Portfolio ITCI Stock Details ITCI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-4,539
Closed -$379K – 968
2024
Q4 		$379K Buy
+4,539
New +$373K 0.07% 377
2022
Q3 		– Sell
-6,008
Closed -$343K – 1455
2022
Q2 		$343K Buy
+6,008
New +$341K 0.03% 751

Other funds holding ITCI

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $9.85B AUM 55.6% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM
DKCM
Davidson Kempner Capital Management New York $7.33B AUM 56.47% 1-Year Est. Return
UOC
UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return

Occudo Quantitative Strategies's ITCI Position: Q1 2025 in Review

Occudo Quantitative Strategies sold out of Intra-Cellular Therapies Inc. (ITCI) in Q1 2025, closing a stake of 4,539 shares — an estimated $379K sold.

Occudo Quantitative Strategies first reported a position in ITCI in Q2 2022 and held it in 2 quarters. The position peaked at $379K in Q4 2024. 395 funds tracked by Wall St. Rank hold ITCI as of Q1 2025.

  • Occudo Quantitative Strategies reported no remaining Intra-Cellular Therapies Inc. position as of Q1 2025 after selling out during the quarter.
  • Occudo Quantitative Strategies sold 4,539 Intra-Cellular Therapies Inc. shares in Q1 2025, an estimated $379K.
  • Occudo Quantitative Strategies first reported a position in Intra-Cellular Therapies Inc. in Q2 2022 and held it in 2 quarters.
  • Occudo Quantitative Strategies's Intra-Cellular Therapies Inc. position peaked at $379K in Q4 2024.
  • 395 funds tracked by Wall St. Rank held Intra-Cellular Therapies Inc. as of Q1 2025.

Based on Occudo Quantitative Strategies's 13F filing for Q1 2025, filed 15 May 2025.